Cynosure (Nasdaq: CYNO) reported earnings on April 30. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Cynosure beat expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. GAAP earnings per share expanded.

Margins increased across the board.

Revenue details
 Cynosure recorded revenue of $40.7 million. The three analysts polled by S&P Capital IQ foresaw a top line of $38.8 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $34.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.07. The four earnings estimates compiled by S&P Capital IQ predicted $0.13 per share. GAAP EPS of $0.07 for Q1 were 17% higher than the prior-year quarter's $0.06 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 58.2%, 110 basis points better than the prior-year quarter. Operating margin was 4.9%, 240 basis points better than the prior-year quarter. Net margin was 3.0%, 60 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $45.2 million. On the bottom line, the average EPS estimate is $0.18.

Next year's average estimate for revenue is $181.0 million. The average EPS estimate is $0.73.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 371 members out of 386 rating the stock outperform, and 15 members rating it underperform. Among 84 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 77 give Cynosure a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $35.60.

Is Cynosure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.